Filed for bankruptcy in Aug 2024
DMTK - DermTech, Inc.
NASDAQ
->
Healthcare
->
Diagnostics & Research
La Jolla,
United States
Type: Equity
DMTK price evolution
DMTK
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $31.05 | $40.21 | $40.7 | $46.26 |
| Short term investments | $11.4 | $19.12 | $30.97 | $43.41 |
| Net receivables | $2.5 | $2.58 | $3.6 | $3.87 |
| Inventory | $0.83 | $1 | $1.2 | $1.35 |
| Total current assets | $44.2 | $61.75 | $75.93 | $93.74 |
| Long term investments | ||||
| Property, plant & equipment | $55.3 | $56.71 | $58.5 | $59.87 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $58.77 | $60.18 | $61.97 | $63.33 |
| Total investments | $11.4 | $19.12 | $30.97 | $43.41 |
| Total assets | $102.97 | $121.93 | $137.9 | $157.07 |
| Current liabilities | ||||
| Accounts payable | $1.91 | $1.48 | $1.7 | $2.32 |
| Deferred revenue | $0.2 | $0.2 | $0.24 | $0.29 |
| Short long term debt | $3.21 | $3.09 | $2.98 | $2.31 |
| Total current liabilities | $12.52 | $13.45 | $12.64 | $16.01 |
| Long term debt | $50.46 | $51.31 | $52.2 | $52.98 |
| Total noncurrent liabilities | $50.46 | $51.31 | $52.2 | $52.98 |
| Total debt | $53.67 | $54.39 | $55.17 | $55.29 |
| Total liabilities | $62.98 | $64.75 | $64.83 | $69 |
| Shareholders' equity | ||||
| Retained earnings | -$443.94 | -$423.94 | -$404.84 | -$385.68 |
| Other shareholder equity | $0.18 | $0.18 | $0.13 | -$0.1 |
| Total shareholder equity | $39.99 | $57.17 | $73.06 | $88.08 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $40.21 | $81.25 | $179.91 | $24.25 |
| Short term investments | $19.12 | $48.41 | $48.45 | $39.53 |
| Net receivables | $2.58 | $4.17 | $3.85 | $1.48 |
| Inventory | $1 | $1.76 | $0.48 | $0.1 |
| Total current assets | $61.75 | $136.04 | $232.82 | $66.88 |
| Long term investments | ||||
| Property, plant & equipment | $56.71 | $62.38 | $12.29 | $2.73 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $60.18 | $66.04 | $15.48 | $2.9 |
| Total investments | $19.12 | $48.41 | $48.45 | $39.53 |
| Total assets | $121.93 | $202.07 | $248.31 | $69.78 |
| Current liabilities | ||||
| Accounts payable | $1.48 | $2.42 | $2.88 | $1.57 |
| Deferred revenue | $0.2 | $0.11 | $1.38 | $1.54 |
| Short long term debt | $3.09 | $1.75 | $1.57 | $0.11 |
| Total current liabilities | $13.45 | $15.64 | $12.18 | $5.42 |
| Long term debt | $51.31 | $54.08 | $6.28 | $0.23 |
| Total noncurrent liabilities | $51.31 | $54.09 | $6.43 | $0.86 |
| Total debt | $54.39 | $55.83 | $7.86 | $0.34 |
| Total liabilities | $64.75 | $69.72 | $18.61 | $6.29 |
| Shareholders' equity | ||||
| Retained earnings | -$423.94 | -$323.05 | -$206.36 | -$126.36 |
| Other shareholder equity | $0.18 | -$0.77 | -$0.12 | -$0 |
| Total shareholder equity | $57.17 | $132.35 | $229.7 | $63.49 |
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3.85 | $3.92 | $3.92 | $3.98 |
| Cost of revenue | $3.13 | $3.48 | $3.74 | $3.97 |
| Gross Profit | $0.71 | $0.44 | $0.17 | $0.01 |
| Operating activities | ||||
| Research & development | $3.27 | $3.35 | $3.6 | $3.89 |
| Selling, general & administrative | $17.95 | $16.84 | $16.39 | $28.25 |
| Total operating expenses | $21.22 | $20.19 | $19.98 | $32.14 |
| Operating income | -$20.51 | -$19.75 | -$19.81 | -$32.13 |
| Income from continuing operations | ||||
| EBIT | -$20.01 | -$19.09 | -$19.16 | -$31.36 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$20.01 | -$19.09 | -$19.16 | -$31.36 |
| Income (for common shares) | -$20.01 | -$19.09 | -$19.16 | -$31.36 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $15.3 | $14.52 | $5.88 | |
| Cost of revenue | $15.02 | $13.87 | $5.98 | |
| Gross Profit | $0.28 | $0.65 | -$0.1 | |
| Operating activities | ||||
| Research & development | $15.24 | $24.05 | $5.29 | |
| Selling, general & administrative | $88.78 | $94.76 | $29.9 | |
| Total operating expenses | $104.02 | $118.81 | $35.19 | |
| Operating income | -$103.74 | -$118.17 | -$35.29 | |
| Income from continuing operations | ||||
| EBIT | -$100.89 | -$116.68 | -$35.29 | |
| Income tax expense | ||||
| Interest expense | -$0.04 | |||
| Net income | ||||
| Net income | -$100.89 | -$116.68 | -$35.25 | |
| Income (for common shares) | -$100.89 | -$116.68 | -$35.25 | |
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Net income | -$20.01 | -$19.09 | -$19.16 | -$31.36 |
| Operating activities | ||||
| Depreciation | $1.41 | $1.35 | $1.35 | $1.48 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.7 | $3.15 | $3.16 | $7.51 |
| Total cash flows from operations | -$17.12 | -$12.71 | -$19.04 | -$23.2 |
| Investing activities | ||||
| Capital expenditures | $0.16 | -$0.05 | -$0.26 | |
| Investments | $7.83 | $12.08 | $12.81 | $13.32 |
| Total cash flows from investing | $7.83 | $12.24 | $12.76 | $13.06 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.13 | $0.76 | $4.5 | |
| Net borrowings | -$0 | -$0.02 | -$0.03 | -$0.03 |
| Total cash flows from financing | $0.12 | -$0.02 | $0.73 | $4.46 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$9.16 | -$0.49 | -$5.56 | -$5.68 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$100.89 | -$116.68 | -$78.33 | -$35.25 |
| Operating activities | ||||
| Depreciation | $5.85 | $4.46 | $2.3 | $0.49 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $18.57 | $18.93 | $13.28 | $4.97 |
| Total cash flows from operations | -$76.98 | -$95.26 | -$62.11 | -$28.68 |
| Investing activities | ||||
| Capital expenditures | -$0.9 | -$3.31 | -$2.72 | -$1.83 |
| Investments | $30.77 | -$1.01 | -$9.79 | -$39.51 |
| Total cash flows from investing | $29.86 | -$4.32 | -$12.51 | -$41.34 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $6.19 | $1.05 | $230.45 | $44.31 |
| Net borrowings | -$0.11 | -$0.14 | -$0.17 | -$0.01 |
| Total cash flows from financing | $6.08 | $0.92 | $230.28 | $78.9 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$41.04 | -$98.66 | $155.66 | $8.87 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 34.96M |
| Revenue | $15.66M |
|---|---|
| EBITDA | -$84.05M |
| EBIT | -$89.63M |
| Net Income | -$89.63M |
| Revenue Q/Q | 10.58% |
| Revenue Y/Y | 9.71% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 1.14 |
| Cash/Share | 0.89 |
| EPS | -$2.56 |
|---|---|
| ROA | -68.96% |
| ROE | -138.79% |
| Debt/Equity | 1.13 |
|---|---|
| Net debt/EBITDA | -0.38 |
| Current ratio | 3.53 |
| Quick ratio | 3.46 |